Cigarettes and amyotrophic lateral sclerosis: Only smoke or also fire?†
Marc G. Weisskopf PhD
Departments of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, MA
Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Search for more papers by this authorAlberto Ascherio MD
Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, MA
Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Search for more papers by this authorMarc G. Weisskopf PhD
Departments of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, MA
Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Search for more papers by this authorAlberto Ascherio MD
Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, MA
Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Search for more papers by this authorPotential conflict of interest: Nothing to report.
References
- 1 Gallo V, Bueno-de-Mesquita HB, Vermeulen R, et al. Smoking and risk of amyotrophic lateral sclerosis: analysis of the EPIC cohort. Ann Neurol 2009; 65: 378–385.
- 2 Kamel F, Umbach DM, Munsat TL, et al. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology 1999; 18: 194–202.
- 3 Nelson LM, McGuire V, Longstreth WT Jr, Matkin C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol 2000; 151: 156–163.
- 4 Sutedja NA, Veldink JH, Fischer K, et al. Lifetime occupation, education, smoking, and risk of ALS. Neurology 2007; 69: 1508–1514.
- 5 Weisskopf MG, McCullough ML, Calle EE, et al. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epidemiol 2004; 160: 26–33.
- 6 Fang F, Bellocco R, Hernan MA, Ye W. Smoking, snuff dipping and the risk of amyotrophic lateral sclerosis—a prospective cohort study. Neuroepidemiology 2006; 27: 217–221.
- 7 Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69: 541–550.
- 8 Saeed M, Siddique N, Hung WY, et al. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 2006; 67: 771–776.
- 9 Slowik A, Tomik B, Wolkow PP, et al. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 2006; 67: 766–770.
- 10 Wills AM, Landers JE, Zhang H, et al. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. Neurology 2008; 70: 929–934.
- 11 Lammer EJ, Iovannisci DM, Tom L, et al. Gastroschisis: a gene-environment model involving the VEGF-NOS3 pathway. Am J Med Genet C Semin Med Genet 2008; 148C: 213–218.
- 12 Sathasivam S. VEGF and ALS. Neurosci Res 2008; 62: 71–77.
- 13ATSDR. Toxicological Profile for Formaldehyde. Atlanta, GA: US Department of Health and Human Services, Public Health Service; 1999.
- 14 Weisskopf MG, Morozova N, O'Reilly EJ, et al. Prospective study of chemical exposures and amyotrophic lateral sclerosis mortality. J Neurol Neurosurg Psychiatry (in press).
Citing Literature
